Fed Decision Day: What Higher Treasury Yields Mean for US Markets
Analyzing the impact of rising Treasury yields and Fed decisions on various sectors and market indices.
Merck and Moderna's mRNA-4157: A Breakthrough in Personalized Cancer Vaccines
Merck and Moderna's Phase 3 trial results could reshape the oncology landscape with personalized mRNA cancer vaccines.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
MBody AI's Strategic Shift: $10 Million Offering Fuels Embodied AI Ambitions
MBody AI's recent name change and $10 million offering signal a bold step into the thriving embodied AI market.
Merck and Moderna's Cancer Vaccine: A Game Changer for mRNA Technology?
The Phase 3 INTerpath-001 trial success positions Merck and Moderna at the forefront of mRNA cancer vaccines, potentiall…
GFL Environmental's Take-Private Consideration: Implications for Investors on TSX and NYSE
GFL Environmental's move to explore a take-private transaction raises questions for investors on the TSX and NYSE.
Cogent Biosciences' Bezuclastinib NDA Acceptance: A Key Milestone for Biotech Investors
Cogent Biosciences' NDA acceptance for bezuclastinib marks a pivotal moment for biotech investors, highlighting a signif…
Fifth Third Bancorp's Comerica Acquisition: A $850 Million Synergy Target
Fifth Third Bancorp sets ambitious synergy goals following its acquisition of Comerica, signaling a pivotal moment in re…
Merck and Moderna's Cancer Vaccine Trial Success: A Game Changer for mRNA Oncology
Merck and Moderna's Phase 3 trial success could reshape cancer treatment and impact their stock valuations.
Kimberly-Clark (KMB) and Kenvue (KVUE) Deal Faces EU Scrutiny: An Investor's Perspective
Kimberly-Clark is making concessions for EU approval of its $40B acquisition of Kenvue amid regulatory scrutiny.
Scholar Rock (SRRK) Gains Momentum After FDA Approval: What It Means for Investors
Scholar Rock's stock gains traction following FDA approval of ISEMBYLD, prompting Truist to raise its price target.
Baldwin Group's Strategic Shift to Go Private: Implications for Shareholders
Baldwin Group, Inc. will go private through a strategic acquisition, raising questions for its shareholders.